Entering text into the input field will update the search result below

More good news for Achillion

Jun. 10, 2014 7:14 AM ETAntiaging Quantum Living Inc. (AAQL) StockBy: Douglas W. House, SA News Editor
  • Demonstrating impeccable timing, Achillion Pharmaceuticals (OTC:ACHN) announces that the FDA has lifted its clinical hold on sovaprevir and initial dosing has begun with ACH-3422.
  • Results from the Phase 1 proof-of-concept trial for the uridine-analog nucleotide ACH-3422 are expected in the fall and combination studies should begin by year end.
  • Sovaprevir testing may now begin with a once-daily maximum dose of 200 mg in HCV patients and healthy volunteers. A partial hold is still in effect for multiple dose studies in healthy volunteers which will require FDA approval of the protocol before initiating.
  • Shares are up 34% premarket on higher-than-normal volume.

Recommended For You

More Trending News

About AAQL Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AAQL--
Antiaging Quantum Living Inc.